IPL and MGX Versus MGX Alone in the Treatment of Dry Eye Disease Secondary to MGD

NACompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 15, 2018

Primary Completion Date

April 18, 2019

Study Completion Date

April 18, 2019

Conditions
Dry EyeMeibomian Gland Dysfunction
Interventions
DEVICE

Intense Pulsed Light (IPL) therapy

Intense pulsed light therapy is a non-invasive and non-laser light treatment that is FDA-approved for various conditions in dermatology. Subjects will receive a total of 4 treatments over the course of the study, at intervals of 2 weeks. Each treatment will include applications on 10-15 IPL pulses in the malar region and close to the lower eyelids, followed by meibomian gland expression. Meibomian gland expression will be implemented by squeezing the meibomian glands with the aid of two Q-tips positioned on either side of the meibomian glands, or with a meibomian gland expressor forceps.

DEVICE

Sham therapy

Subjects will receive a total of 4 treatments over the course of the study, at intervals of 2 weeks. Each treatment will include a sham application of IPL on 10-15 locations in the malar region and close to the lower eyelids, followed by meibomian gland expression. Meibomian gland expression will be implemented by squeezing the meibomian glands with the aid of two Q-tips positioned on either side of the meibomian glands, or with a meibomian gland expressor forceps.

Trial Locations (1)

Unknown

Shaare Zedek, Jerusalem

All Listed Sponsors
lead

Lumenis Be Ltd.

INDUSTRY

NCT03265652 - IPL and MGX Versus MGX Alone in the Treatment of Dry Eye Disease Secondary to MGD | Biotech Hunter | Biotech Hunter